Skip to main content
. 2024 Sep 19;19(9):e0310641. doi: 10.1371/journal.pone.0310641

Table 2. Clinical characteristics, complete blood examination and bone marrow analyses of CMML patients in the PREACH-M trial stratified as CBL mutant vs. RAS pathway wildtype.

Variable Total (n = 17) RAS pathway wildtype (n = 6) CBL mutant (n = 11) P-value
Gender
 Male, n (%) 8 (47%) 2 (33%) 6 (55%) 0.6199
 Female, n (%) 11 (65%) 4 (67%) 5 (45%)
Age (years)
 Mean (range) 72 (56−86) 73 (56−86) 71 (56−79) 0.2539
WHO classification
 CMML-0, n (%) 3 (18%) 1 (17%) 2 (18%) 0.7964
 CMML-1, n (%) 9 (53%) 4 (67%) 5 (45%)
 CMML-2, n (%) 5 (29%) 1 (17%) 4 (36%)
 MD-CMML, n (%) 7 (41%) 4 (67%) 3 (27%) 0.1618
 MP-CMML, n (%) 10 (59%) 2 (33%) 8 (73%)
BM Blast (%)
 Mean (range) 7.7 (1.0−17.0) 5.3 (1.0−10.3) 10.1 (4.0−17.0) 0.0457
WCC (×109/L)
 Mean (range) 20.3 (4.9−74.1) 13.8 (4.9−36.8) 26.8 (6.9−74.1) 0.0462
Hb (g/L)
 Mean (range) 106 (79−128) 104 (79−124) 107 (91−128) 0.4893
PLT (×109/L)
 Mean (range) 89 (7−219) 91 (7−219) 88 (27−192) 0.5000
Neutrophils (109/L)
 Mean (range) 10.6 (1.7−45.2) 7.2 (1.7−23.3) 14.0 (3.0−45.2) 0.0608
Monocytes (109/L)
 Mean (range) 4.3 (0.7−12.2) 3.1 (1.0−8.0) 5.6 (0.7−12.2) 0.0859
CRP (mg/L)
 Mean (range) 4.4 (1.7−18.9) 5.2 (1.7−18.9) 3.6 (0.7−7.3) 0.4708
Spleen craniocaudal length (cm)
 Mean (range) 13.6 (10.2−20.6) 12.0 (10.8−13.8) 15.2 (10.2−20.6) 0.0308

n number of patients; BM bone marrow; WCC white blood cell count; Hb haemoglobin; PLT platelet; CRP C-reactive protein; MD-CMML myelodysplastic CMML; MP-CMML myeloproliferative CMML

Mann-Whitney test was applied to continuous and Fisher’s exact test to categorical data for statistical analysis where P<0.05 was statistically significant.

2016 WHO Classification:

Based on BM blast %: CMML-0 PB <2%, BM <5%; CMML-1 PB 2–4%, BM 5–9%, CMML-2 PB>5%, BM 10–19%.

Based on WCC: MD-CMML WCC<13×109/L, MP-CMML WCC>13×109/L